Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes

Cancer Gene Therapy

Volumn 9, Issue 12, 2002, Pages 1022-1035

  Hermiston, Terry W ^a   Kuhn, Irene ^a  

^a BAYER AG   (Germany)

Author keywords

Armed therapeutic virus; Cancer; Gene therapy; Oncolytic virus

Indexed keywords

ANGIOGENESIS INHIBITOR; CD11 ANTIGEN; CYTOCHROME P450 2B1; CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; ONCOLYTIC VIRUS; ONYX 015; PRODRUG; PROTEIN P53; THYMIDINE KINASE; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT;

ADENOVIRUS; ADENOVIRUS 5; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA REPLICATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GENE AMPLIFICATION; GENE MUTATION; GENE THERAPY; GENETIC ENGINEERING; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; MEASLES VIRUS; MELANOMA; NEOVASCULARIZATION (PATHOLOGY); NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROSTATE CANCER; REOVIRUS; REVIEW; SAFETY; SOLID TUMOR; TRANSGENE; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; ANIMAL; GENE VECTOR; GENETICS; METHODOLOGY; NEOPLASM; ONCOGENE; VIROLOGY; VIRUS;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; MEASLES VIRUS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE; POLIOVIRUS; REOVIRUS SP.; SIMPLEXVIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; GENES, TUMOR SUPPRESSOR; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES; PRODRUGS; TRANSGENES; VIRUS REPLICATION; VIRUSES;

EID: 0036903141     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700542     Document Type: Review

References (159)

1. Wildner O. Oncolytic viruses as therapeutic agents. Ann Med. 2001;33:291-304.
2. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol. 2002;83(Pt 3):491-502.
3. Kirn D. Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer. Oncogene. 2000;19:6660-6669.
4. Hermiston T. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J Clin Invest. 2000;105:1169-1172.
5. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879-885.
6. Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9:1211-1218.
7. Kim D. Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer. Oncogene. 2000;19:6660-6669.
8. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther. 2001;8:1618-1626.
9. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication- selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19:289-298.
10. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: Results of a phase I trial. Gene Ther. 2000;7:867-874.
11. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000;7:859-866.
12. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20: 2251-2266.
13. Csatary LK, Moss RW, Beuth J, et al. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res. 1999;19:635-638.
14. Csatary LK, Bakacs T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA. 1999;281:1588-1589.
15. Kirn D, Niculesco-Duvaz I, Halden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med. 2002;8:S68-S73.
16. Hermiston T. Fighting fire with fire: Attacking the complexity of human tumors with armed therapeutic viruses. Curr Opin Mol Ther. 2002;4:334-342.
17. McCormick F. Cancer gene therapy: Fringe or cutting edge? Nat Rev Cancer. 2001;1:130-141.
18. Wilson DR. Viral-mediated gene transfer for cancer treatment. Curr Pharmacol Biotechnol. 2002;3:151-164.
19. Willis AC, Chen X. The promise and obstacle of p53 as a cancer therapeutic agent. Curr Mol Med. 2002;2:329-345.
20. Levine A, DiMiao D, Coen DM. Fields Virology (Fourth Edition). 2001;1:3-18, 119-132.
21. Nishizaki M, Fujiwara T, Tanida T, et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect. Clin Cancer Res. 1999;5:1015-1023.
22. Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 1995;377:646-649.
23. Mueller H. Tumor necrosis factor as an antineoplastic agent: Pitfalls and promises. Cell Mol Life Sci. 1998;54:1291-1298.
24. Sauthoff H, Pipiya T, Heitner S, et al. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther. 2002 (In press).
25. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276-5281.
26. Stribbling SM, Friedlos F, Martin J, et al. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum Gene Ther. 2000;11:285-292.
27. Knox RJ. Gene-directed enzyme prodrug therapy (GDEPT) - Recognizing the present limitations of gene therapy for the treatment of cancer. Curr Opin Invest Drugs. 2001;2:835-838.
28. Freytag SO, Kim JH, Khil MS, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for local recurrence of prostate cancer. Proc Am Assoc Cancer Res. 2002;43 (Abstract 5429).
29. Hawkins LK, Hermiston T. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the E3B region. Gene Ther. 2001;8:1142-1148.
30. van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther. 2002;2:307-322.
31. Ichikawa T, Chiocca EA. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or defective viral vector. Cancer Res. 2001;61:5336-5339.
32. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther. 1998;9:1323-1333.
33. Wildner O, Morris JC. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J Gene Med. 2000;2:353-360.
34. McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 2000;7:1217-1223.
35. Ichikawa T, Petros WP, Ludeman SM, et al. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res. 2001;61:864-868.
36. Lee YJ, Galoforo SS, Battle P, et al. Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene Ther. 2001;8:397-404.
37. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000;18:609-622.
38. Sanchez-Prieto R, Quintanilla M, Cano A, et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene. 1996;13:1083-1092.
39. Toyoizumi T, Mick R, Abbas AE, et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther. 1999;10:3013-3029.
40. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000;60:1009-1013.
41. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985;43:175-203.
42. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
43. Thompson WD, Li WW, Maragoudakis M. The clinical manipulation of angiogenesis: Pathology, side-effects, surprises, and opportunities with novel human therapies. J Pathol. 2000;190:330-337.
44. Folkman J. Therapeutic angiogenesis in ischemic limbs. Circulation. 1998;97:1108-1110.
45. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990;9:267-282.
46. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197-1202.
47. Talks KL, Harris AL. Current status of antiangiogenic factors. Br J Haematol. 2000;109:477-489.
48. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer. 2000;89:1181-1194.
49. Kleinman HK, Liau G. Gene therapy for antiangiogenesis. J Natl Cancer Inst. 2001;93:965-967.
50. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999;284:808-812.
51. Coussens LM, Fingleton B, Matrisian LM. Matrix metallo-proteinase inhibitors and cancer: Trials and tribulations. Science. 2002;295:2387-2392.
52. Lund EL, Bastholm L, Kristjansen PE. Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res. 2000;6:971-978.
53. Bello L, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 2001;61:7501-7506.
54. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296:2404-2407.
55. Savontaus MJ, Sauter BV, Huang TG, Woo SL. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther. 2002;9:972-979.
56. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
57. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol. 1996;24:859-862.
58. Steinman RM, Pack M, Inaba K. Dendritic cell development and maturation. Adv Exp Med Biol. 1997;417:1-6.
59. Lanzavecchia A. Identifying strategies for immune intervention. Science. 1993;260:937-944.
60. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
61. Dallal RM, Lotze MT. Immunotherapy of metastasis. Surg Oncol Clin North Am. 2001;10:433-447, xi.
62. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood. 1997;90:1458-1470.
63. + one marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med. 1995;182:1111-1119.
64. Chinnaiyan AM, Hanna WL, Orth K, et al. Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3. Curr Biol. 1996;6:897-899.
65. Froelich CJ, Dixit VM, Yang X. Lymphocyte granule-mediated apoptosis: Matters of viral mimicry and deadly proteases. Immunol Today. 1998;19:30-36.
66. Alderson MR, Tough TW, Davis-Smith T, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995;181:71-77.
67. Lynch DH, Alderson MR, Ramsdell F. Immunoregulatory effects of Fas-mediated signalling. J Cell Biochem. 1996;60:39-46.
68. Dranoff G. Tumor immunology: Immune recognition and tumor protection. Curr Opin Immunol. 2002;14:161-164.
69. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev. 2002;13:143-154.
70. Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol. 2002;12:33-42.
71. Hellstrom I, Hellstrom KE. Tumor immunology: An overview. Ann NY Acad Sci. 1993;690:24-33.
72. Hellstrom KE, Hellstrom I, Linsley P, Chen L. On the role of costimulation in tumor immunity. Ann NY Acad Sci. 1993;690:225-230.
73. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993;53:5610-5612.
74. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993;53:5613-5616.
75. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995;16:487-494.
76. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunol Today. 1997;18:292-299.
77. Hersey P. Impediments to successful immunotherapy. Pharmacol Ther. 1999;81:111-119.
78. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol. 1997;159:4415-4425.
79. Sogn JA. Tumor immunology: The glass is half full. Immunity. 1998;9:757-763.
80. Ling W, Rayman P, Uzzo R, et al. Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha. Blood. 1998;92:1334-1341.
81. Drake CG, Pardoll DM. Tumor immunology - Towards a paradigm of reciprocal research. Semin Cancer Biol. 2002;12:73-80.
82. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2:227-238.
83. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: The Fas counterattack. Dis Esophagus. 1999;12:83-89.
84. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
85. Gimmi CD, Morrison BW, Mainprice BA, et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med. 1996;2:1367-1370.
86. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA. 1996;93:11341-11348.
87. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998;5:121-130.
88. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest. 2000;106:763-771.
89. Wong RJ, Patel SG, Kim S, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther. 2001;12:253-265.
90. Bennett JJ, Malhotra S, Wong RJ, et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg. 2001;233:819-826.
91. Hawkins LK, Johnson L, Bauzon M, et al. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7 K/gp19 K region. Gene Ther. 2001;8:1123-1131.
92. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: Association with stage and reversal by resection. Br J Cancer. 2000;82:1009-1012.
93. Roizman B. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA. 1996;93:11307-11312.
94. Kiessling R, Wasserman S, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999;48:353-362.
95. Li E, Stupack D, Bokuch GM, Nemerow GR. Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. J Virol. 1998;72:8806-8812.
96. Roymans D, Slegers H. Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem. 2001;268:487-498.
97. Hawkins LK, Hermiston TW. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region. Gene Ther. 2001;8:1132-1141.
98. Nanda D, Vogels R, Havenga M, et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res. 2001;61:8743-8750.
99. Katso R, Okkenhaug K, Ahmadi K, et al. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615-675.
100. Berrie CP. Phosphoinositide 3-kinase inhibition in cancer treatment. Expert Opin Invest Drugs. 2001;10:1085-1098.
101. Hawkins LK, Lemoine NR, Kim D. Oncolytic biotherapy: A novel therapeutic platform. Lancet Oncol. 2002;3:17-26.
102. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med. 2001;7:781-787.
103. Timiryasova TM, Li J, Chen B, et al. Antitumor effect of vaccinia virus in glioma model. Oncol Res. 1999;11:133-144.
104. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282:1332-1334.
105. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821-825.
106. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798-806.
107. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (d11520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002;20:1562-1569.
108. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
109. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Ther. 2001;8:308-315.
110. Habib N, Salama H, Abd El Latif Abu Median A, et al. Clinical trial of E1B-deleted adenovirus (d11520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 2002;9:254-259.
111. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002;62:4968-4976.
112. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999;59:410-413.
113. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy. Nat Med. 2000;6:1134-1139.
114. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19:2-12.
115. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res. 2001;7:120-126.
116. Howe JA, Demers GW, Johnson DE, et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther. 2000;2:485-495.
117. Doronin K, Toth K, Kuppuswamy M, et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000;74:6147-6155.
118. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol. 2001;75:3314-3324.
119. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61: 7464-7472.
120. Chen Y, DeWeese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 2001;61:5453-5460.
121. Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001;61:517-525.
122. Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther. 2002;9:270-281.
123. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell. 2002;1:325-337.
124. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther. 1999;10:1721-1733.
125. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res. 2002;62:4663-4670.
126. Ramachandra M, Rahman A, Zou A, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol. 2001;19:1035-1041.
127. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: Potent antitumoral efficacy but no toxicity to normal cell. Cancer Res. 2002;62:3438-3447.
128. Takahashi M, Sato T, Sagawa T, et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther. 2002;5:627-634 (Part 1).
129. Fabra A, Parada C, Vinyals A, et al. Intravascular injections of a conditional replicative adenovirus (ad1118) prevent metastatic disease in human breast carcinoma xenografts. Gene Ther. 2001;8:1627-1634.
130. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
131. + between immediate early gene 1 and the "a" sequence. J Gen Virol. 1991;72:631-639.
132. Delman KA, Bennett JJ, Zager JS, et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther. 2000;11:2465-2472.
133. Pyles RB, Warnick RE, Chalk CL, Szanti BE, Parysek LM. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther. 1997;8:533-544.
134. Parker LP, Wolf JK, Price JE. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines. Ann Clin Lab Sci. 2000;30:395-405.
135. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res. 2002;62:2306-2312.
136. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol. 1998;16:444-448.
137. Pawlik TM, Nakamura H, Mullen JT, et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer. 2002;95:1171-1181.
138. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994;54:3963-3966.
139. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994;54:5745-5751.
140. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA. 2001;98:6396-6401.
141. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997;71:5124-5132.
142. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252:854-856.
143. Chung RY, Saeki Y, Chiocca EA. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol. 1999;73: 7556-7564.
144. Nakamura H, Mullen JT, Chandrasekhar S, et al. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res. 2001;61:5447-5452.
145. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery. 1993;32:597-603.
146. Whitman ED, Tsung K, Paxson J, Norton JA. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery. 1994;116:183-188.
147. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther. 1999;10:649-657.
148. Peplinski GR, Tsung K, Meko JB, Norton JA. Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses. Ann Surg Oncol. 1996;3:15-23.
149. Peplinski GR, Tsung K, Casey MJ, et al. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta. Cancer J Sci Am. 1996;2:21.
150. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999;6:409-422.
151. Gnant MF, Puhlmann M, Alexander HR Jr, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 1999;59:3396-3403.
152. Mukherjee S, Haenel T, Himbeck R, et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. Cancer Gene Ther. 2000;7:663-670.
153. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999;59:5800-5807.
154. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61:8751-8757.
155. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2002;13:641-652.
156. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA. 2000;97:6803-6808.
157. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol. 2001;75:3474-3749.
158. Peng KW, TenEcyck CJ, Galanis E, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002;62:4656-4662.
159. Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001;98:2002-2007.